Relative Bioavailability of Meloxicam 2 x 7.5 mg Tablets Compared to 15 mg Tablet and Dose Proportionality Over a Dose Range of 7.5 mg and 15 mg in Healthy Volunteers

Inclusion Criteria: * Healthy subjects as determined by results of screening * Written informed consent in accordance with Good Clinical Practice (GCP) and local legislation * Age \>= 18 and \<= 50 years * Broca \>= -20% and \<= + 20 % Exclusion Criteria: * Any finding of the medical examination (including laboratory blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * Surgery of the gastro-intestinal tract (except appendectomy) * Diseases of the central nervous system (such as epilepsy) or psychiatric disorders * Chronic or relevant acute infections * Hypersensitivity to meloxicam and/or non-steroidal antirheumatic agents * Intake of drugs with a long half-life (\>24 hours) (\<= 1 month prior to administration or during the trial) * Use of any drugs which might influence the results of the trial (\<= 10 days prior to administration or during the trial) * Participation in another trial with an investigational drug (\<= 2 months prior to administration or during the trial) * Smoker (\>= 10 cigarettes or \>= 3 cigars or \>= 3 pipes/day) * Inability to refrain from smoking on study days * Alcohol abuse * Drug abuse * Blood donation (\<= 1 months prior to administration) * Excessive physical activities (\<= 5 days prior to administration) * History of hemorrhagic diatheses * History of gastro-intestinal ulcer, perforation or bleeding * History of bronchial asthma For female subjects: * Pregnancy * Positive pregnancy test * No adequate contraception e.g. sterilization, intrauterine device (IUD), oral contraceptives * Inability to maintain this adequate contraception during the whole study period * Lactating